Table 2.
Characteristics of women with uterine corpus cancer (UCC*), ages 15 to 79 years, diagnosed 1973 to 2003, who were initially treated with surgery only or with surgery and radiotherapy, SEER Program.†
| Characteristics | Surgery only | Surgery and radiotherapy |
|||
|---|---|---|---|---|---|
| Any radiotherapy | Combination therapy‡ | External beam therapy | Brachytherapy | ||
| Persons at risk | 37 534 | 23 415 | 5 650 | 10 464 | 6 605 |
| Person-years at risk | 386 284 | 254 791 | 51 845 | 106 812 | 89 356 |
| Mean survival time after UCC diagnosis (yrs) | 10 | 11 | 9 | 10 | 14 |
| Mean age at UCC diagnosis (yrs) | 60 | 62 | 62 | 63 | 61 |
| Age at UCC diagnosis (yrs) | |||||
| <45 | 2 980 (8%) | 1 135 (5%) | 297 (5%) | 454 (4%) | 339 (5%) |
| 45–54 | 7 653 (20%) | 3 833 (16%) | 912 (16%) | 1 490 (14%) | 1 320 (20%) |
| 55–64 | 12 995 (35%) | 8 456 (36%) | 1 987 (35%) | 3 609 (34%) | 2 635 (40%) |
| 65–79 | 13 906 (37%) | 9 991 (43%) | 2 454 (43%) | 4 911 (47%) | 2 311 (35%) |
| Calendar year of UCC diagnosis | |||||
| <1980 | 7 534 (20%) | 7 653 (33%) | 1 320 (23%) | 2 910 (28%) | 3 245 (49%) |
| 1980–1989 | 11 168 (30%) | 7 971 (34%) | 1 989 (35%) | 3 671 (35%) | 2 115 (32%) |
| 1990–1999 | 14 133 (38%) | 6 052 (26%) | 1 735 (31%) | 3 131 (30%) | 932 (14%) |
| ≥2000 | 4 699 (13%) | 1 739 (7%) | 606 (11%) | 752 (7%) | 313 (5%) |
| Race | |||||
| White | 34 030 (91%) | 21 426 (92%) | 5 049 (89%) | 9 481 (91%) | 6 258 (95%) |
| Black | 1 278 (3%) | 958 (4%) | 280 (5%) | 437 (4%) | 207 (3%) |
| Other | 2 226 (6%) | 1 031 (4%) | 321 (6%) | 546 (5%) | 140 (2%) |
| Chemotherapy | |||||
| Yes | 1 018 (3%) | 946 (4%) | 247 (4%) | 504 (5%) | 126 (2%) |
| No | 36 511 (97%) | 22 456 (96%) | 5 401 (96%) | 9 953 (95%) | 6 475 (98%) |
| Unknown | 5 (0%) | 13 (0%) | 2 (0%) | 7 (0%) | 4 (0%) |
| Tumor stage | |||||
| Localized | 34 238 (91%) | 16 628 (71%) | 3 170 (56%) | 7 365 (70%) | 5 604 (85%) |
| Regional | 1 774 (5%) | 4 707 (20%) | 1 951 (35%) | 2 005 (19%) | 628 (10%) |
| Distant | 987 (3%) | 1 401 (6%) | 406 (7%) | 791 (8%) | 146 (2%) |
| Unknown | 535 (1%) | 679 (3%) | 123 (2%) | 303 (3%) | 227 (3%) |
| Persons with a second cancer diagnosis§ | 4 136 | 3 292 | 734 | 1 421 | 1 048 |
| Mean time between 1st and 2nd cancer (yrs) | 10 | 10 | 10 | 10 | 12 |
*
Includes patients with endometrial adenocarcinoma or carcinoma (sarcomas and other cell types excluded) who survived one or more years. The numbers of specific radiotherapy do not match exactly to numbers of any radiotherapy because of unknown specific radiotherapy (N=696).
†
National Cancer Institute’s Surveillance, Epidemiology, and End Results Program.
‡
Combination therapy is external beam therapy and brachytherapy.
§
Includes all primary second cancers (excluding female genital system and non-melanoma skin cancer).